Why Is Viridian Therapeutics Stock Falling Monday?

Viridian Therapeutics Inc. (NASDAQ:VRDN) shares are down during Monday’s premarket session following the announcement of topline results from the REVEAL-1 Phase 3 clinical trial for elegrobart, for thyroid eye disease (TED). Viridian Therapeutics Trial Meets Primary...